Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
New Model Anti-infectives
Destiny Pharma is not just developing novel anti-infective drugs - its lead product XF-73 is in the US and European Phase 2b study for a new preventative indication that had not been awarded to any other drug before. The clinical study of XF-73, which has proven antimicrobial activity, is expected to report an interim review in August 2020. As anti-infectives have higher probabilities of success than other therapeutic areas, Destiny’s destiny looks bright.
Many august healthcare organisations such as the World Health Organisation and US Centers for Disease Control and Prevention have warned about the shortage of new antimicrobial agents to fight the global threat of antimicrobial resistance (AMR). However, many biotech companies have fallen into the trap of developing new anti-infective treatments in indications where there is no unmet medical need, or where generic competition already exists. Destiny Pharma’s novel first drug neatly side-steps all of these issues by developing XF-73 for the prevention of post-surgical staphylococcal infections.
Destiny’s fruitful discussions with the FDA have resulted in recruitment recommencing in earnest and is now up to 77 patients. A smart protocol adaption has been agreed which reduces enrolment to 125 patients without compromising the power of the study’s primary endpoint. The study is now about two thirds enrolled. This is a positive development since it saves Destiny money and time; and should ensure recruitment completion by the end of 2020.
We use a risk-adjusted NPV model to value Destiny Pharma based only on the development costs, our expectations of future milestone and licensing revenues for XF-73, and Destiny’s cash. Our fair value of Destiny Pharma is £86.3m or 197p per share.Download Now Missing Out Get our research first
WHY CHOOSE ED
"Many thanks to @equity_research for a superb Investor Forum. $BMK.L , $VLG.L & $VP.L all interesting companies. I recommend these events. "
"We cannot thank you enough for opening our eyes to private investors."
"MHP believes commissioned research is an important part of the toolkit to attract new investors and improve liquidity. We rate ED's analysts and research very highly as one of the leading providers in this space."
"One of the biggest problems private investors have, is getting access to broker research. It’s basically impossible for many investors. Therefore I feel some commissioned research is really important and a good investment for companies. In my experience ED are far more proactive than other firms in this space."
Blogger and Stockopedia Contributor
"There is a need now, more than ever before, for real insight and clarity to be brought to company messages for investors….I would strongly recommend Equity Development to the management of any company."
Small Cap Equity Salesman
"From early days as a private company through to being established on AIM, I have always been able to rely on ED for wise counsel, perceptive research and introductions to new, supportive shareholders."
"I would like to thank and congratulate you, particularly Liz, on your note. It’s short, sharp, pulls out the key issues and I believe will be a valuable asset for our retail outreach."
"The team at ED consistently produce high quality research and highlight profitable investment opportunities, an invaluable tool for small cap investors in this under researched space."
"I thoroughly enjoyed the investor evening again, and as before its good that you get such an interested audience who engage and ask us all decent questions."